Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III
Top-Line Psoriasis Efficacy Bested Placebo; Safety Similar To Phase II
Executive Summary
Bristol Myers Squibb released no detailed data from the first Phase III trial of deucravacitinib (BMS-986165) in psoriasis but said it achieved superiority to placebo and Otezla with safety similar to Phase II.
You may also be interested in...
Takeda Will Take TYK2 Inhibitor Into Phase III, Looks For Dosing Edge Over BMS Rival
The Japanese pharma company has bet big on its TYK2 inhibitor, but it must demonstrate competitive safety and efficacy if it is to challenge Bristol Myers Squibb’s first-to-market Sotyktu.
Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis
Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.
Amgen’s Otezla And BMS’s Sotyktu Battle For Share In Oral Psoriasis Drug Market
Amgen and Bristol defended their positions in the post-topical/pre-biologic segment of the psoriasis market during their Q4 earnings calls, now that each company has an oral drug available.